Ibandronic acid Sandoz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
N/0021 
Minor change in labelling or package leaflet not 
06/07/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0020 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/10/2020 
11/10/2021 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/07/2016 
29/06/2017 
SmPC, 
PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
R/0017 
Renewal of the marketing authorisation. 
25/02/2016 
13/04/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Ibandronic acid Sandoz in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0018 
C.I.z - Changes (Safety/Efficacy) of Human and 
08/12/2015 
13/04/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0016/G 
This was an application for a group of variations. 
06/11/2015 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.z - Quality change - Active substance - Other 
variation 
IA/0015 
A.7 - Administrative change - Deletion of 
24/09/2015 
n/a 
manufacturing sites 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/09/2015 
13/04/2016 
SmPC, Annex 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
T/0013 
Transfer of Marketing Authorisation 
18/02/2015 
19/03/2015 
SmPC, 
Labelling and 
PL 
IA/0012 
A.5.b - Administrative change - Change in the name 
23/12/2014 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/08/2014 
19/03/2015 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IB/0008 
C.I.11.z - Introduction of, or change(s) to, the 
06/03/2014 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0009 
C.I.8.a - Introduction of or changes to a summary of 
15/01/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0005 
To add a new manufacturer of the active substance. 
27/06/2013 
n/a 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
supported by an ASMF 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/05/2013 
03/06/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
N/0006 
Minor change in labelling or package leaflet not 
21/02/2013 
03/06/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0004 
B.II.d.2.d - Change in test procedure for the finished 
20/09/2012 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IAIN/0003 
C.I.9.i - Changes to an existing pharmacovigilance 
30/08/2012 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
IB/0002/G 
This was an application for a group of variations. 
08/02/2012 
31/10/2012 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
II, Labelling 
and PL 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Page 5/5 
 
 
 
 
 
 
 
